Butyrate.

Inulin is fermented by bifidobacteria into acetate and lactate, which butyrate-producing species such as Faecalibacterium and Roseburia take up and convert into butyrate. Supplemental butyrate supplies the end product directly while inulin feeds the colon's own production.

Glutamine is the main oxidative fuel of small intestinal enterocytes, and butyrate supplies most of the energy colonocytes burn. Each covers the part of the gut lining that actually oxidises it.

PHGG ferments slowly along the length of the colon and is one of the more butyrogenic soluble fibres, so short chain fatty acid production continues distally. Oral butyrate is largely taken up higher in the tract.

Lactobacillus strains produce lactate, which butyrate-forming gut bacteria convert onward through the butyryl-CoA route. That is the same production chain supplemental butyrate bypasses.

Colonic bacteria ferment pectin to short-chain fatty acids including butyrate, so the fibre supplies endogenous production while an oral butyrate dose supplies it directly. Feeding the producers and dosing the product address the same colonocyte fuel from both ends.

Psyllium is partly fermented in the colon and raises short-chain fatty acid output, while its gel slows transit and gives fermenters more contact time. That supports the same butyrate supply to colonocytes.

Oat beta-glucan is fermented by saccharolytic gut bacteria into acetate, propionate and butyrate. It raises endogenous butyrate production in the same compartment an oral butyrate dose serves.

Guar galactomannan is fermented in the colon to short-chain fatty acids with a butyrate share, the same rationale behind its partially hydrolysed form. Substrate and product are two routes to one fuel.

Vitamin D receptor signalling raises expression of tight-junction proteins in intestinal epithelium, and butyrate raises the same barrier proteins through histone deacetylase inhibition. Two independent inputs to normal barrier integrity.

Zinc supports tight-junction assembly and mucosal repair enzymes, and butyrate is the preferred energy substrate colonocytes burn to do that repair. Long-standing gut formulas pair the fuel with the mineral for that reason.

Slippery elm mucilage forms a physical coat over mucosa while butyrate supplies the metabolic fuel epithelial cells use to maintain that mucosa. The mechanical and metabolic roles do not overlap.

Activated charcoal adsorbs small organic acids and the fermentable substrates that generate them, so taking it in the same window lowers what reaches the colon. Separate the doses by several hours.

Carvacrol and thymol are broadly membrane-active against gut bacteria, including the saccharolytic genera that ferment fibre into butyrate. Running them alongside a prebiotic fibre works against the endogenous butyrate supply.

Resistant starch escapes small-intestinal digestion and reaches the colon intact, where saccharolytic bacteria ferment it. Butyrate is one of the principal short-chain fatty acids produced, and resistant starch is among the substrates most consistently linked to butyrate rather than acetate or propionate. Supplying the substrate feeds endogenous production, which is a different route to the same molecule than swallowing a butyrate salt.

Fructooligosaccharides are fermented by colonic bacteria, raising short-chain fatty acid production including butyrate through cross-feeding. Bifidobacteria consume the oligosaccharide and release lactate and acetate, which butyrate-producing species then convert onward. That cross-feeding step is why a prebiotic that does not itself yield butyrate can still raise it.

Galactooligosaccharides are selectively fermented in the colon, feeding bifidobacteria that release acetate and lactate. Butyrate-producing species use those intermediates as their own substrate. The result is more butyrate from a substrate that produces little of it directly.

Bifidobacteria are acetate and lactate producers rather than butyrate producers. Butyrate-forming species such as Faecalibacterium and Anaerostipes take up that acetate and lactate and convert them onward to butyrate. This cross-feed is one of the better-characterised relationships in colonic microbial ecology.

Lactate produced by lactobacilli is a substrate for lactate-utilising butyrate producers such as Anaerostipes and Eubacterium species. Whether the cross-feed happens depends on which butyrate producers are present, so the effect is conditional on the resident community rather than automatic.

Like other bifidobacteria, this species ferments carbohydrate to acetate and lactate rather than to butyrate. Those products are the feedstock for butyrate producers downstream. Pairing the organism with a fermentable fibre is what supplies the carbon in the first place.

An animal study examined bovine colostrum together with sodium butyrate and reported effects on gut microbial composition and on markers along the intestinal-liver axis. This was measured in animals, so it grounds a mechanistic pairing rather than a human effect. The two act through different routes, colostrum through immunoglobulins and growth factors and butyrate as a colonocyte fuel and HDAC inhibitor.

A veterinary trial combined dietary betaine with protected calcium butyrate and reported effects on growth performance and blood biochemistry. The finding is in production animals, not people, and the study cannot separate the contribution of either compound. It is recorded here as a co-administration with a measured outcome in that species.

A systematic review of polyphenol supplementation examined gut microbiota composition and faecal short-chain fatty acid concentrations, of which butyrate is one. Polyphenols reach the colon largely unabsorbed and act as substrate and as selective pressure on the community. Faecal short-chain fatty acid concentration is a marker of the colonic environment, not an outcome in itself.

Most ingested resveratrol reaches the colon, where the microbiota metabolises it and where it in turn shifts community composition. Reviews of polyphenol supplementation report accompanying changes in faecal short-chain fatty acids including butyrate. These are compositional and marker changes, and they vary widely between individuals.

Konjac glucomannan is a viscous soluble fibre that resists digestion and is fermented in the colon, contributing to short-chain fatty acid production. Its viscosity also slows transit through the upper gut, which changes where and how quickly fermentation begins. Substrate supply is the lever here rather than any direct chemistry with butyrate itself.

Soluble beta-glucans reach the colon largely intact and are fermented to short-chain fatty acids. The fermentation profile depends on the source and on molecular weight, so the proportion appearing as butyrate rather than acetate varies between preparations. This is a substrate relationship, not a claim about a specific product.

This yeast does not itself produce butyrate. It changes the colonic environment and the bacterial community around it, and studies in that area report accompanying shifts in short-chain fatty acid production. The connection runs through the community rather than through shared chemistry, which is why it sits at the lower confidence band.

Calcium butyrate is one of the mineral salts used to make butyric acid handleable as a powder, because the free acid is a volatile liquid with a strong odour. The calcium is a counter-ion that contributes to the mineral load and to the tablet weight, not an active partner. Any calcium-related interaction, such as competition with iron or zinc for absorption, belongs to the calcium and not to the butyrate.

Sodium butyrate is the form used in most published work because it is stable, crystalline and easy to dose. The sodium counter-ion adds to total sodium intake, which is worth noting for anyone counting it. It has no role in the butyrate chemistry itself.

Magnesium butyrate exists as an alternative mineral salt of the same acid. As with any magnesium salt, the mineral itself has an osmotic effect in the gut at higher intakes. That effect belongs to the magnesium and should be counted against total magnesium intake rather than attributed to butyrate.

Lactoferrin sequesters iron and interacts with the mucosal surface, while butyrate acts as the primary fuel for colonocytes and influences tight junction protein expression. Both are described in preclinical work on barrier integrity, by different routes. No human combination trial grounds this pairing, so it stays at the lowest confidence band.

Bile acids reaching the colon are transformed by the resident microbiota and in turn shape which species thrive there, including butyrate producers. Supplemental bile therefore changes the environment in which butyrate is made. The direction of that change is not predictable from first principles and no combination data supports a specific claim.